GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Cyclically Adjusted PS Ratio

Aspira Womens Health (FRA:CUL) Cyclically Adjusted PS Ratio : 2.24 (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Cyclically Adjusted PS Ratio?

As of today (2024-05-24), Aspira Womens Health's current share price is €2.08. Aspira Womens Health's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.93. Aspira Womens Health's Cyclically Adjusted PS Ratio for today is 2.24.

The historical rank and industry rank for Aspira Womens Health's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:CUL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.39   Med: 6.38   Max: 110.44
Current: 2.29

During the past years, Aspira Womens Health's highest Cyclically Adjusted PS Ratio was 110.44. The lowest was 0.39. And the median was 6.38.

FRA:CUL's Cyclically Adjusted PS Ratio is ranked better than
51.49% of 134 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.37 vs FRA:CUL: 2.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aspira Womens Health's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.167. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.93 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aspira Womens Health Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Aspira Womens Health's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Cyclically Adjusted PS Ratio Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.96 80.96 22.61 4.59 4.09

Aspira Womens Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.03 3.01 4.85 4.09 3.05

Competitive Comparison of Aspira Womens Health's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Aspira Womens Health's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Cyclically Adjusted PS Ratio falls into.



Aspira Womens Health Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Aspira Womens Health's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.08/0.93
=2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Womens Health's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Aspira Womens Health's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.167/131.7762*131.7762
=0.167

Current CPI (Mar. 2024) = 131.7762.

Aspira Womens Health Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.100 100.560 0.131
201409 0.105 100.428 0.138
201412 0.519 99.070 0.690
201503 0.306 99.621 0.405
201506 0.166 100.684 0.217
201509 0.088 100.392 0.116
201512 0.095 99.792 0.125
201603 0.130 100.470 0.171
201606 0.181 101.688 0.235
201609 0.159 101.861 0.206
201612 0.219 101.863 0.283
201703 0.188 102.862 0.241
201706 0.214 103.349 0.273
201709 0.153 104.136 0.194
201712 0.168 104.011 0.213
201803 0.131 105.290 0.164
201806 0.131 106.317 0.162
201809 0.132 106.507 0.163
201812 0.161 105.998 0.200
201903 0.141 107.251 0.173
201906 0.199 108.070 0.243
201909 0.180 108.329 0.219
201912 0.181 108.420 0.220
202003 0.170 108.902 0.206
202006 0.101 108.767 0.122
202009 0.153 109.815 0.184
202012 0.171 109.897 0.205
202103 0.174 111.754 0.205
202106 0.200 114.631 0.230
202109 0.190 115.734 0.216
202112 0.219 117.630 0.245
202203 0.230 121.301 0.250
202206 0.261 125.017 0.275
202209 0.268 125.227 0.282
202212 0.245 125.222 0.258
202303 0.260 127.348 0.269
202306 0.274 128.729 0.280
202309 0.212 129.860 0.215
202312 0.187 129.419 0.190
202403 0.167 131.776 0.167

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aspira Womens Health  (FRA:CUL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Aspira Womens Health Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (FRA:CUL) Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines